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Heat shock proteins (HSPs) are evolutionarily conserved molecules and play important 
roles in fundamental cellular processes. They serve as molecular chaperones and hence 
provide a protective function in ensuring cell survival and repair of cellular damage after 
a stressful stimulus. This paper summarizes the current knowledge about the different 
roles of HSPs in aging and disease, focusing on the neurodegenerative disorders of 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and prion disease.  
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HEAT SHOCK PROTEINS 
Heat shock proteins (HSPs), also known as stress proteins, were first discovered in 1962 by Ritossa[1], 
who observed that a transient increase in temperature induced puffing patterns in the chromosomes of 
salivary glands of Drosophila melanogaster larvae. Temperature increases were subsequently found to 
stimulate expression of proteins with molecular masses of 26 and 70 kDa[2]. These proteins were termed 
“heat shock proteins”, as their expression was up-regulated in response to cellular insults, such as raised 
temperature, oxidative stress, chemicals, and irradiation[3]. Indeed, intracellular concentrations of HSPs 
are known to increase by approximately two- to threefold after cellular exposure to insults that induce 
protein misfolding or aggregation, or when there is a flux of newly synthesized non-native proteins[4]. 
HSPs are generally organized into different families according to their approximate molecular size or 
function – HSP100, HSP90, HSP70, HSP60, HSP40, and small HSPs (sHSPs) with molecular sizes 
ranging from 15 to 30 kDa[5]. They are present in the nucleus and the cytoplasm, as well as in 
cytoplasmic organelles, such as mitochondria and endoplasmic reticulum. Most HSPs function as 
molecular chaperones and help to maintain protein homeostasis within the cell. They provide protection 
against protein aggregation, facilitate the folding of newly synthesized polypeptides and refolding of 
proteins that have been damaged, and target and sequester proteins that have been severely damaged for 
degradation[4,6,7,8,9,10]. High molecular weight HSPs are known as ATP-dependent chaperones, 
assisting in the folding of newly synthesized or damaged proteins in an ATP-dependent active process, 
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while sHSPs work in an ATP-independent manner[11]. A chaperone usually does not act alone, but is 
aided by other molecules, often other chaperones or several smaller cochaperones (such as HSP60 with 
HSP10, and HSP90 with HSP70)[12]. Although many proteins can fold to their native state 
spontaneously without the aid of any other molecular components in vitro, molecular chaperones are 
often required for protein folding to occur in a highly efficient manner in vivo[13].  
HSPs AND AGING 
Various post-translational modifications occur within the lifespan of a stable protein[14]. These include 
oxidation, deamination, glycation, phosphorylation, acetylation, nitrosylation, and protein truncation from 
cleavage or deletion of N- or C-terminal residues[15,16]. Accumulation of misfolded proteins poses a 
danger to an aging cell. Since molecular chaperones such as HSPs are only capable of associating with 
misfolded proteins to prevent their aggregation, a more drastic mechanism, such as protein degradation, 
must be utilized in order to protect the cell from the potential toxicity of these proteins. Furthermore, 
induced expression of chaperones has been found to be impaired in the aged organism[17]. 
Protein degradation can occur by the action of proteasome, the key proteolytic apparatus, aided by 
various chaperones[8]. In the aged cell, decreased activity of the proteasome has been reported[18]. 
Moreover, glycated, oxidized, and aggregated proteins are often effective inhibitors of the 
proteasome[19,20]. Thus, accumulation of misfolded proteins coupled with a proteolytic apparatus with 
reduced effectiveness would result in a buildup of protein aggregates. These may then have harmful 
effects on cellular function and give rise to diseases associated with aging, particularly in neurons and 
other postmitotic cells[21].  
HSPs AND NEURODEGENERATIVE DISORDERS 
An identifying characteristic of neurodegenerative disorders, such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and Creutzfeldt-Jakob disease (CJD), is the 
formation of brain lesions possessing intracellular or extracellular deposits of protein aggregates[13,22]. 
These disorders are postulated to result from toxic effects of misfolded proteins[13] (Fig. 1).  
Alzheimer’s Disease 
AD is late-onset dementia, presenting with progressive loss of memory, inability to recognize people and 
objects, and reduction in task performance. Neuronal degeneration is observed in the central nervous 
system, particularly in the basal forebrain and the hippocampus[23]. Neurofibrillary tangles (NFT) and β-
amyloid (Aβ) plaques are defining features associated with AD. Microtubule-associated tau proteins are 
known to be hyperphosphorylated in AD, resulting in misfolding and formation of abnormal filaments, 
which eventually aggregate to produce NFTs[24]. Aβ is also involved in the pathogenesis of AD[25].  
Elevated expression of the sHSPs αB-crystallin and HSP27/28, as well as of HSP70, has been 
reported in patients suffering from AD[26,27]. HSP27/28 and αB-crystallin may increase the 
neurotoxicity of Aβ 1-40 peptide by maintaining the peptide in a nonfibrillar, highly toxic form. On the 
other hand, sHSPs have also been reported to inhibit Aβ aggregation and effectively block the 
cerebrovascular toxicity of Aβ[28]. Both HSP70 and HSP90 facilitate solubilization of tau proteins and 
promote partitioning of tau into a productive folding pathway to form microtubules, thereby preventing 
aggregation of these proteins into NFTs. In addition, HSP70 and HSP90 are associated with accelerated 
tau degradation[24].  




FIGURE 1. Misfolded proteins and neurodegenerative disorders. External stresses, 
such as heat shock, hypoxia, and mechanical stress, induce the production of 
reactive oxygen species and denaturation of cellular proteins. Moderated stress on 
the cell system induces HSP expression. These HSPs are capable of ensuring proper 
folding or treatment of misfolded proteins, as well as inhibiting protein aggregation, 
thus preventing neurodegenerative diseases that result from high stress–induced cell 
death[29]. 
Parkinson’s Disease 
PD is an age-related, neurodegenerative movement disorder characterized by progressive degeneration of 
dopaminergic neurons in the substantia nigra. The hallmark of PD is accumulation of α-synuclein (AS), 
the main component of Lewy bodies in midbrain dopaminergic neurons[29]. Examination of the 
aggregated proteins in Lewy bodies of PD patients showed the presence of several HSPs[30]. In addition, 
patient glial cells have been reported to express αB-crystallin. Coexpression of HSP70 with AS has been 
shown to inhibit the formation of AS fibrils and reduce their toxicity, both in vitro as well as in vivo in 
Drosophila and mouse, possibly by binding of HSP70 to prefibrillar AS[31,32,33]. Indeed, Huang et al. 
have demonstrated that this inhibition occurs through the binding of HSP70 with various intermediate 
structures[34]. Dietary restriction has been shown to induce HSP70 and Grp78 expression, resulting in 
protection against PD[35].  
Huntington’s Disease 
HD is a progressive, neurodegenerative disorder resulting from expansion of a CAG repeat that codes for 
polyglutamine in the N-terminus of the huntington protein. It is characterized by selective neuronal loss, 
primarily in the cortex and striatum. This results in alterations in movement, memory, and mood[36]. 
Polyglutamine repeats make proteins more vulnerable to aggregation. A significant feature of 
polyglutamine diseases is the formation of neuronal inclusions that consist of insoluble, granular, and 
fibrous deposits[36]. Increased levels of HSP40, HSP60, HSP70, and HSP100 have been shown to inhibit 
polyglutamine-induced protein aggregation and thus impede disease progression[8,37,38,39,40]. 




The central feature of prion diseases is the aggregation of pathologic prion proteins, such as PrPSc, an 
abnormal isoform of the cellular prion protein[41]. Prion has been held responsible for a number of 
degenerative brain diseases, including CJD in man, bovine spongiform encephalopathy in cows, and 
scrapie in sheep. The key event in CJD is the extracellular deposition of aggregates of PrPSc in the brain 
of affected individuals. It is thought that cellular toxicity is conferred either by PrPSc aggregates or, more 
likely, by the process of their formation[13]. In scrapie, amyloidogenic proteins such as PrPSc have been 
postulated to cause neuronal injury and, subsequently, death. Elevated HSP72 levels have been reported 
in astrocytes, which may have been produced to act as a molecular chaperone to prevent the formation or 
deposition of neurotoxic proteins, and also to target those proteins for degradation[42]. Interestingly, 
studies have shown that bovine cellular prion protein PrPc is able to bind to αB-crystallin. However, it is 
not known if this association can prevent the formation of PrP fibrils and neurotoxicity[43]. 
CONCLUSION 
HSPs are essential molecular chaperones in the cell, functioning to preserve the correct conformation of 
proteins and also to repair misfolded proteins. As discussed above, a large body of evidence supports the 
involvement of HSPs in neurodegenerative disorders. Understanding the various mechanisms involved in 
the formation of inclusion bodies in the pathophysiological development of neurodegenerative disorders 
would aid in the quest for therapeutic alternatives. Knowledge of the roles played by HSPs in protein 
aggregation and subsequent toxicity may lead to novel treatment approaches to neurodegenerative 
disorders by targeting the fate of misfolded proteins. 
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